ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis. (December 2017)

• Record Type: Journal Article
• Authors: Madrid-Paredes, Adela; Cañadas-Garre, Marisa; Sánchez-Pozo, Antonio; Expósito-Ruiz, Manuela; Calleja-Hernández, Miguel Ángel
• Is Part Of: Surgical oncology. Volume 26:Number 4(2017)
• Page Start: 473
• Page End: 482
• Publication Date: 2017-12
• Subjects: Meta-analysis -- ABCB1 -- C3435T -- C1236T -- Breast -- Cancer; ABCB1 (ATP-binding cassette, B1) -- ACT (Adjuvant Chemotherapy) -- BC (Breast Cancer) -- FAC (Fluouracil-Adryamicin-Cyclophosphamide) -- FEC (Fluouracil-Epirubicin-Cyclophosphamide) -- LABC (Locally Advance Breast Cancer) -- MBC (Metastatic Breast Cancer) -- NACT (Neoadjuvant Chemotherapy) -- SNP (Single Nucleotide Polymorphism); Cancer -- Surgery -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Electronic journals; 616.994059
• DOI: 10.1016/j.suronc.2017.09.004
• Languages: English
• ISSNs: 0960-7404

Abstract

Abstract: The ABCB1 gene encodes the P -glycoprotein, an efflux pump for some antineoplastic agents which acts as a resistance mechanism to chemotherapy. Three SNPs (C3435T, C1236T and G2677T/A), are the most widely studied in ABCB1. The inconsistent conclusions about the association of these polymorphisms and the response to chemotherapy in breast cancer (BC) patients prompted us to conduct a meta-analysis. A total of nine (770 patients), five (566 patients) and three studies (367 patients) relating the ABCB1 C3435T, C1236T and G2677T/A polymorphisms respectively, were included. The main analysis revealed a lack of association between ABCB1 polymorphisms and response to chemotherapy in every genetic model: C3435T (dominant OR: 0.888; 95%CI: 0.558–1.413), C1236T (dominant OR: 1.968; 95%CI: 0.609–6.362) and G2677T/A (GG vs GT + GA + TT + TA + AA OR: 0.854; 95%CI: 0.418–1.744). Stratification by ethnicity, cancer type and response criteria did not change the pattern of results. The available evidence indicates that three polymorphisms within ABCB1; C3435T, C1236T and G2677T/A, cannot be considered a reliable predictor of response to chemotherapy in BC patients.